In a report released today, Alan Carr from Needham maintained a Buy rating on Alnylam Pharma (ALNY), with a price target of $135. The company’s shares opened today at $82.34.
Carr said:
“Alnylam reported $12.1M in 4Q18 WW Onpattro sales. The company pre-announced $11-12M in early Jan 2019. No sales guidance yet, but mgmt noted over 200 pts WW on drug and company has received 250 U.S. start forms as of YE18. No apparent resistance from payers. Givosiran Phase 3 trial results in Porphyria next month is key near-term development milestone. Based on available data, we expect positive outcome. Mgmt reiterated guidance for NDA/ MAA submissions mid-2019. Stock remains attractive given productive platform. Lumasiran and inclisiran programs to also generate Phase 3 data later this yr (unch). BUY.”
According to TipRanks.com, Carr is a 4-star analyst with an average return of 2.5% and a 41.6% success rate. Carr covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Iterum Therapeutics Plc.
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $117.70, representing a 42.9% upside. In a report issued on January 28, Chardan Capital also maintained a Buy rating on the stock with a $150 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $153.99 and a one-year low of $60.27. Currently, Alnylam Pharma has an average volume of 896K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
